Product Information
TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.2938 per EA under NDC 31722053530. Its NADAC has been published 449 times since Feb 28, 2018.
FDA first approved this application on Jan 26, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722053530
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA090636FDA Approved
1/26/2018
TE Code
AB
On Market Since
1/26/2018
Pharmacological Classes
Price Statistics
The NADAC for TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET has been published 449 times since Feb 28, 2018, and over the history we have for it it has declined 98.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2938 per EA |
|---|---|
| All-time high | $27.7425 (Mar 14, 2018) |
| All-time low | $0.2938 (Sep 23, 2026) |
| 52-week high | $0.3721 |
| 52-week low | $0.2938 |
| Median price | $0.5585 |
| Average price | $1.1626 |
| Largest weekly change | -87.4% (Apr 18, 2018) |
| Weeks tracked | 449 |
| Tracking since | Feb 28, 2018 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tenofovir Disoproxil Fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.2938 per EA (NDC 31722053530), effective Sep 30, 2026.
How has the price of TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET has declined 98.9%. It has been tracked across 449 weekly CMS publications since Feb 28, 2018.
What are the highest and lowest recorded NADAC prices for TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET?
Since Feb 28, 2018, the NADAC for TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET has ranged from a low of $0.2938 (Sep 23, 2026) to a high of $27.7425 (Mar 14, 2018), with a median of $0.5585 per EA.
Are there cheaper alternatives to TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET?
TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET (NDC 31722053530) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.